The Clinical Guide to Supportive and Palliative Care for HIV/AIDS

A Clinical Guide to Supportive and Palliative Care for HIV/AIDS • Chapter 9: Dermatologic Problems26 picasREFERENCES1. Uthayakumar S, Nandwani R, Drinkwater T, Nayagam AT, Darley CR. The prevalence of skin disease inHIV infection and its relationship to the degree of immunosuppression. Br J Dermatol 137:595-8, 1997.2. Rosatelli JB, Machado A, Roselino AM. Dermatoses among Brazilian HIV-positive patients: correlation withthe evolutionary phases of AIDS. Int J Dermatol 36:729-34, 1997.3. Munoz-Perez MA, Rodriguez-Pichardo A, Colmenero MA. Dermatological findings correlated with CD4lymphocyte counts in a prospective 3 year study of 1161 patients with human immunodeficiency virus diseasepredominantly acquired through intravenous drug use. Br J Dermatol 139:33-9, 1998.4. Majors MJ, Cockerell CJ, Cruz PD Jr. Pruritus in HIV-infected individuals: an algorithmic approach andreview of selected pruritic eruptions. Unpublished data.5. Sadick NS, McNutt NS, Kaplan MH. Papulosquamous dermatoses of AIDS. J Am Acad Dermatol22:1270-7, 1990.6. Kaplan MH, Sadick N, McNutt NS, et al. Dermatologic findings and manifestations of acquired immunodeficiencysyndrome (AIDS). J Am Acad Dermatol 16:485-506, 1987.7. Cronin TA, Resnik BI, Elgart G, Kerdel FA. Recalcitrant giant molluscum contagiosum in a patient with AIDS.J Am Acad Dermatol 35:266-7, 1996.8. Elmets CA. Management of common superficial fungal infections in patients with AIDS. J Am Acad Dermatol31:S61-3,1994.9. Vazquez JA. Options for the management of mucosal candidiasis in patients with AIDS and HIV infection.Pharmacotherapy 19:76-87, 1999.10. Stevens DA. Management of systemic manifestations of fungal disease in patients with AIDS. J Am AcadDermatol 31:S64-7, 1994.11. Meinking TL, Taplin D, Hermida JL, Pardo R, Kerdel FA. The treatment of scabies with ivermectin.N Engl J Med 333:26-30, 1995.12. Martin JN, Osmond DH. Kaposi’s sarcoma-associated herpesvirus and sexual transmission of cancer risk.Curr Opin Oncol 11:508-15,1999.13. Ensoli B, Barillari G, Salahuddin SZ, et al. Tat protein of HIV-1 stimulates growth of cells derived fromKaposi’s sarcoma lesions of AIDS patients. Nature 344:84-6, 1990.14. Mesri EA. Inflammatory reactivation and angiogenicity of Kaposi’s sarcoma-associated herpesvirus/HHV8: amissing link in the pathogenesis of acquired immunodeficiency syndrome-associated Kaposi’s sarcoma.Blood 93:4031-3, 1999.15. Dezube BJ. New therapies for the treatment of AIDS-related Kaposi sarcoma. Curr Opin Oncol 12:445-9, 2000.16. Ledergerber B, Telenti A, Egger M. Risk of HIV-related Kaposi’s sarcoma and non-Hodgkin’s lymphoma withpotent antiretroviral therapy: prospective cohort study. Br Med J 319:23-4, 1999.17. Mitsuyasu R, Groopman J, Volberding P. Cutaneous reactions to trimethoprim-sulfamethoxazole in patientswith AIDS and Kaposi’s sarcoma. N Engl J Med 308:1535-6, 1983.18. De Raeve L, Song M, Van Maldergem L. Adverse cutaneous drug reactions in AIDS. Br J Dermatol119:521-3, 1988.19. Sanwo M, Nwadiuko R, Beall G. Use of intravenous immunoglobulin in the treatment of severe cutaneousdrug reactions in patients with AIDS. J Allergy Clin Immunol 98: 1112-5, 1996.20. Beall G., Sanwo M., Hussain H. Drug reactions and desensitization in AIDS. Immunol Allergy Clin North Am17:319-37, 1997.202U.S. Department of Health and Human Services • Health Resources and Services Administration • HIV/AIDS Bureau